Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
NCT ID: NCT03924869
Last Updated: 2025-12-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
448 participants
INTERVENTIONAL
2019-06-25
2025-01-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary study hypothesis is SBRT plus pembrolizumab prolongs Event-free Survival (EFS) compared to SBRT plus placebo (normal saline solution).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)
NCT03050554
Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer
NCT03574220
Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer
NCT03867175
Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer
NCT03348748
Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma
NCT03307759
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SBRT + Pembrolizumab
Participants receive SBRT once every 3 days for 3, 4, 5, or 8 fractions (dependent on tumor type/location; 45-70 Gray \[Gy\] total) over approximately 2 weeks PLUS pembrolizumab 200 mg via intravenous (IV) infusion once every 3 weeks for up to 17 cycles (up to approximately 1 year). Each cycle is 21 days.
Stereotactic Body Radiotherapy (SBRT)
SBRT will be administered once every 3 days for 3, 4, 5, or 8 fractions (dependent on tumor type/location; 45-70 Gray \[Gy\] total) over approximately 2 weeks.
Pembrolizumab
Pembrolizumab will be administered at 200 mg via IV infusion once every 3 weeks for up to 17 cycles (up to approximately 1 year).
SBRT + Placebo
Participants receive SBRT once every 3 days for 3, 4, 5, or 8 fractions (dependent on tumor type/location; 45-70 Gy total) over approximately 2 weeks PLUS placebo (normal saline solution) via IV infusion once every 3 weeks for up to 17 cycles (up to approximately 1 year). Each cycle is 21 days.
Stereotactic Body Radiotherapy (SBRT)
SBRT will be administered once every 3 days for 3, 4, 5, or 8 fractions (dependent on tumor type/location; 45-70 Gray \[Gy\] total) over approximately 2 weeks.
Placebo
Placebo (normal saline solution) will be administered at 200 mg via IV infusion once every 3 weeks for up to 17 cycles (up to approximately 1 year).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Stereotactic Body Radiotherapy (SBRT)
SBRT will be administered once every 3 days for 3, 4, 5, or 8 fractions (dependent on tumor type/location; 45-70 Gray \[Gy\] total) over approximately 2 weeks.
Pembrolizumab
Pembrolizumab will be administered at 200 mg via IV infusion once every 3 weeks for up to 17 cycles (up to approximately 1 year).
Placebo
Placebo (normal saline solution) will be administered at 200 mg via IV infusion once every 3 weeks for up to 17 cycles (up to approximately 1 year).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cannot undergo thoracic surgery due to existing medical illness(es) as determined by the site's multi-disciplinary tumor board. Medically operable participants who decide to treat with stereotactic body radiotherapy (SBRT) as definitive therapy rather than surgery are also eligible, if patient's unwillingness to undergo surgical resection is clearly documented
* Has a Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
* Is able to receive SBRT and does not have an ultra-centrally located tumor
* Has adequate organ function within 7 days prior to the start of study treatment
* A female is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: a) not a women of childbearing potential (WOCBP) OR b) A WOCBP and uses contraceptive method that is highly effective (with a failure rate of \<1% per year), or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), during the intervention period and for at least 120 days after the last dose of pembrolizumab/placebo and 180 days after the last radiotherapy dose
* Male participants are eligible to participate if they agree to the following during the intervention period and for at least 90 days after the last dose of radiotherapy: refrain from donating sperm plus either be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent or must agree to use contraception per study protocol, unless confirmed to be azoospermic
* Has a radiation therapy plan approved by the central radiation therapy quality assurance vendor
Exclusion Criteria
* Has received prior radiotherapy to the thorax, including radiotherapy to the esophagus, mediastinum, or breast
* Has received a live vaccine within 30 days prior to the first dose of study intervention
* Has received an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention administration
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment
* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. A prior NSCLC that occurred and was treated curatively at least 2 years prior to the date of the current diagnosis would be considered a separate primary lung cancer, and therefore an additional malignancy. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast c carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
* Has a known hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients
* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
* Has a known history of Hepatitis B or known active Hepatitis C virus infection
* Has an active autoimmune disease that has required systemic treatment in past 2 years, except replacement therapy
* Has an active infection requiring systemic therapy
* Has a known history of human immunodeficiency virus (HIV) infection
* Has a known history of active tuberculosis (TB; Bacillus tuberculosis)
* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of pembrolizumab/placebo and 180 days after the last radiotherapy dose
* Have not adequately recovered from major surgery or have ongoing surgical complications
* Has had an allogenic tissue/solid organ transplant
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama ( Site 0099)
Birmingham, Alabama, United States
Infirmary Cancer Care ( Site 3044)
Mobile, Alabama, United States
Alaska Oncology and Hematology ( Site 3063)
Anchorage, Alaska, United States
Banner MD Anderson Cancer Center ( Site 3029)
Gilbert, Arizona, United States
CARTI Cancer Center ( Site 3045)
Little Rock, Arkansas, United States
USC Norris Comprehensive Cancer Center ( Site 0007)
Los Angeles, California, United States
Veterans Affairs Palo Alto Health Care System ( Site 3039)
Palo Alto, California, United States
National Jewish Health ( Site 0010)
Denver, Colorado, United States
Yale University ( Site 0011)
New Haven, Connecticut, United States
Mid Florida Hematology and Oncology Center ( Site 0067)
Orange City, Florida, United States
H. Lee Moffitt Cancer Center and Research Institute ( Site 0016)
Tampa, Florida, United States
Goshen Center for Cancer Care ( Site 0022)
Goshen, Indiana, United States
Franciscan Health Indianapolis ( Site 0024)
Indianapolis, Indiana, United States
University of Kentucky School of Medicine & Hospitals ( Site 0026)
Lexington, Kentucky, United States
Sinai Hospital of Baltimore ( Site 3011)
Baltimore, Maryland, United States
William E. Kahlert Regional Cancer Center ( Site 3031)
Westminster, Maryland, United States
Massachusetts General Hospital-Cancer Center Protocol Office ( Site 3007)
Boston, Massachusetts, United States
Mass General / North Shore Center for Outpatient Care ( Site 3040)
Danvers, Massachusetts, United States
University of Massachusetts ( Site 0029)
Worcester, Massachusetts, United States
Sanford Bemidji ( Site 0080)
Bemidji, Minnesota, United States
University of Minnesota ( Site 0069)
Minneapolis, Minnesota, United States
University of Missouri Hospital ( Site 3058)
Columbia, Missouri, United States
Cox Medical Center North-Cox Medical Center/Hulston Cancer Center/ Radiation Oncology ( Site 3060)
Springfield, Missouri, United States
St. Vincent Healthcare Frontier Cancer Center ( Site 3012)
Billings, Montana, United States
John Theurer Cancer Center at Hackensack University Medical Center ( Site 3036)
Hackensack, New Jersey, United States
Rutgers Cancer Institute of New Jersey ( Site 0043)
New Brunswick, New Jersey, United States
Hematology-Oncology Associates of CNY ( Site 3055)
East Syracuse, New York, United States
Mount Sinai Hospital ( Site 0046)
New York, New York, United States
Westchester Medical Center ( Site 3057)
Valhalla, New York, United States
White Plains Hospital ( Site 3014)
White Plains, New York, United States
Sanford Health Roger Maris Cancer Center ( Site 0079)
Fargo, North Dakota, United States
Lehigh Valley Hospital- Cedar Crest ( Site 3005)
Allentown, Pennsylvania, United States
St. Luke's University Health Network ( Site 3006)
Bethlehem, Pennsylvania, United States
Penn State University Milton S. Hershey Medical Center ( Site 0064)
Hershey, Pennsylvania, United States
Fox Chase Cancer Center ( Site 0051)
Philadelphia, Pennsylvania, United States
Allegheny General Hospital ( Site 3028)
Pittsburgh, Pennsylvania, United States
Lankenau Medical Center ( Site 3041)
Wynnewood, Pennsylvania, United States
Sanford Cancer Center Oncology Clinic ( Site 0053)
Sioux Falls, South Dakota, United States
Mountain States Health Alliance ( Site 3054)
Johnson City, Tennessee, United States
University of Tennessee Medical Center Knoxville ( Site 3010)
Knoxville, Tennessee, United States
Vanderbilt University Medical Center ( Site 0075)
Nashville, Tennessee, United States
Cancer Care Northwest ( Site 0063)
Spokane Valley, Washington, United States
Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0206)
ABB, Buenos Aires F.D., Argentina
Hospital Britanico de Buenos Aires ( Site 0204)
Buenos Aires, Buenos Aires F.D., Argentina
Sanatorio Parque ( Site 0207)
Rosario, Santa Fe Province, Argentina
Hospital Provincial del Centenario ( Site 0205)
Rosario, Santa Fe Province, Argentina
IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 0208)
Buenos Aires, , Argentina
Hospital Aleman ( Site 0200)
Buenos Aires, , Argentina
Instituto Medico Especializado Alexander Fleming ( Site 0203)
Buenos Aires, , Argentina
CEMIC ( Site 0201)
Buenos Aires, , Argentina
Port Macquarie Base Hospital ( Site 2500)
Port Macquarie, New South Wales, Australia
GenesisCare North Shore ( Site 2508)
St Leonards, New South Wales, Australia
Royal Brisbane and Women s Hospital ( Site 2502)
Herston, Queensland, Australia
Icon Cancer Centre Hobart ( Site 2507)
Hobart, Tasmania, Australia
Austin Health ( Site 2501)
Melbourne, Victoria, Australia
Landeskrankenhaus - Universitatsklinikum Graz ( Site 0804)
Graz, Styria, Austria
Universitatsklinik LKH Innsbruck ( Site 0802)
Innsbruck, Tyrol, Austria
Keppler Universitatsklinikum ( Site 0806)
Linz, Upper Austria, Austria
Social Medical Center - Otto Wagner Hospital ( Site 0801)
Vienna, Vienna, Austria
Irmandade da Santa Casa de Misericordia de Porto Alegre ( Site 0318)
Porto Alegre, Rio Grande do Sul, Brazil
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 0301)
Porto Alegre, Rio Grande do Sul, Brazil
Clínica de Oncologia Reichow ( Site 0319)
Blumenau, Santa Catarina, Brazil
Hospital e Maternidade Celso Pierro ( Site 0313)
Campinas, São Paulo, Brazil
Instituto Nacional Do Cancer Jose Alencar Gomes Da Silva ( Site 0305)
Rio de Janeiro, , Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0300)
São Paulo, , Brazil
Hospital Paulistano - Amil Clinical Research ( Site 0316)
São Paulo, , Brazil
A.C. Camargo Cancer Center ( Site 0312)
São Paulo, , Brazil
Moncton Hospital - Horizon Health Network ( Site 0105)
Moncton, New Brunswick, Canada
Health Sciences North Research Institute ( Site 0107)
Greater Sudbury, Ontario, Canada
Kingston Health Sciences Centre ( Site 0100)
Kingston, Ontario, Canada
Trillium Health Partners - Credit Valley Hospital ( Site 0102)
Mississauga, Ontario, Canada
The Ottawa Hospital ( Site 0104)
Ottawa, Ontario, Canada
Sault Area Hospital ( Site 0101)
Sault Ste. Marie, Ontario, Canada
CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0110)
Montreal, Quebec, Canada
McGill University Health Centre ( Site 0113)
Montreal, Quebec, Canada
CHUS - Hopital Fleurimont ( Site 0111)
Sherbrooke, Quebec, Canada
CHU Poitiers ( Site 1109)
Poitiers, Ain, France
CHU de Brest -Site Hopital Morvan ( Site 1100)
Brest, Finistere, France
Institut Bergonie ( Site 1102)
Bordeaux, Gironde, France
Institut Regional du Cancer de Montpellier - ICM ( Site 1108)
Montpellier, Herault, France
CHU de Rouen ( Site 1113)
Rouen, Seine-Maritime, France
Hopital Sud du Amiens ( Site 1115)
Amiens, Somme, France
Institut Curie ( Site 1112)
Paris, , France
Hopital Cochin ( Site 1107)
Paris, , France
A.P.H. Paris. Hopital Bichat Claude Bernard ( Site 1114)
Paris, , France
Klinikum Esslingen-Klinik für Kardiologie und Pneumologie ( Site 1208)
Esslingen am Neckar, Baden-Wurttemberg, Germany
Universitaetsklinikum Heidelberg. ( Site 1204)
Heidelberg, Baden-Wurttemberg, Germany
Universitaetsklinikum Erlangen ( Site 1209)
Erlangen, Bavaria, Germany
UKGM Gießen/Marburg-Medical Clinic V ( Site 1210)
Giessen, Hesse, Germany
Pius Hospital Oldenburg ( Site 1202)
Oldenburg, Lower Saxony, Germany
Universitaetsklinikum Essen ( Site 1201)
Essen, North Rhine-Westphalia, Germany
Evangelisches Krankenhaus Hamm gGmbH ( Site 1205)
Hamm, North Rhine-Westphalia, Germany
Charite Universitaetsmedizin Berlin ( Site 1207)
Berlin, , Germany
Pécsi Tudományegyetem Klinikai Központ-Onkoterápiás Intézet ( Site 2314)
Pécs, Baranya, Hungary
CRU Hungary KFT ( Site 2309)
Miskolc, Borsod-Abauj Zemplen county, Hungary
Bacs-Kiskun Varmegyei Oktatokorhaz-Onkoradiologiai Kozpont ( Site 2311)
Kecskemét, Bács-Kiskun county, Hungary
Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz ( Site 2312)
Székesfehérvár, Fejér, Hungary
Petz Aladar Megyei Oktato Korhaz ( Site 2305)
Győr, Győr-Moson-Sopron, Hungary
Debreceni Egyetem Klinikai Kozpont ( Site 2301)
Debrecen, Hajdú-Bihar, Hungary
Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház ( Site 2310)
Szolnok, Jász-Nagykun-Szolnok, Hungary
Törökbálinti Tüdőgyógyintézet ( Site 2302)
Törökbálint, Pest County, Hungary
Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 2307)
Kaposvár, Somogy County, Hungary
Farkasgyepui Tudogyogyintezet ( Site 2313)
Farkasgyepű, Veszprém megye, Hungary
Semmelweis University ( Site 2303)
Budapest, , Hungary
Orszagos Koranyi Pulmonologiai Intezet ( Site 2304)
Budapest, , Hungary
Orszagos Koranyi Pulmonologiai Intezet ( Site 2306)
Budapest, , Hungary
Orszagos Onkologiai Intezet ( Site 2308)
Budapest, , Hungary
Ospedale Santissima Annunziata ( Site 1303)
Chieti, , Italy
A.O. Universitaria Careggi ( Site 1301)
Florence, , Italy
Policlinico di Modena ( Site 1306)
Modena, , Italy
Policlinico Agostino Gemelli ( Site 1302)
Roma, , Italy
Azienda Ospedaliera S. Giovanni Addolorata-Oncologia Medica ( Site 1309)
Roma, , Italy
Aichi Cancer Center Hospital ( Site 2804)
Nagoya, Aichi-ken, Japan
National Cancer Center Hospital East ( Site 2800)
Kashiwa, Chiba, Japan
Kurume University Hospital ( Site 2815)
Kurume, Fukuoka, Japan
Kobe Minimally Invasive Cancer Center ( Site 2811)
Kobe, Hyōgo, Japan
University of Tsukuba Hospital ( Site 2809)
Tsukuba, Ibaraki, Japan
Sendai Kousei Hospital ( Site 2814)
Sendai, Miyagi, Japan
Kansai Medical University Hospital ( Site 2808)
Hirakata, Osaka, Japan
Osaka Medical and Pharmaceutical University Hospital ( Site 2813)
Takatsuki, Osaka, Japan
University of Yamanashi Hospital ( Site 2807)
Chūō, Yamanashi, Japan
Chiba University Hospital ( Site 2806)
Chiba, , Japan
National Hospital Organization Kyushu Cancer Center ( Site 2816)
Fukuoka, , Japan
Hiroshima University Hospital ( Site 2810)
Hiroshima, , Japan
Niigata Cancer Center Hospital ( Site 2801)
Niigata, , Japan
Osaka International Cancer Institute ( Site 2812)
Osaka, , Japan
Tokyo Metropolitan Komagome Hospital ( Site 2802)
Tokyo, , Japan
The Cancer Institute Hospital of JFCR ( Site 2803)
Tokyo, , Japan
Showa University Hospital ( Site 2805)
Tokyo, , Japan
Ziekenhuis Rijnstate ( Site 1405)
Arnhem, Gelderland, Netherlands
Tergooiziekenhuizen, locatie Hilversum-Oncology ( Site 1407)
Hilversum, North Holland, Netherlands
Meander Medisch Centrum-Studie Team Oncologie ( Site 1403)
Amersfoort, Utrecht, Netherlands
Auckland City Hospital ( Site 2900)
Grafton, Auckland, New Zealand
St Olavs Hospital ( Site 1504)
Trondheim, Sor-Trondelag, Norway
Helse Bergen HF Haukeland Universitetssykehus ( Site 1502)
Bergen, Vestfold, Norway
Oslo Universitetssykehus HF Ulleval Sykehus ( Site 1500)
Oslo, , Norway
Centrum Onkologii im. prof. Franciszka ukaszczyka-Ambulatorium Chemioterapii ( Site 2407)
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie ( Site 2400)
Krakow, Lesser Poland Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
Warsaw, Masovian Voivodeship, Poland
Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2403)
Gliwice, Silesian Voivodeship, Poland
SPZOZ MSWIA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie ( Site 2404)
Olsztyn, Warmian-Masurian Voivodeship, Poland
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii ( Site 2402)
Lodz, Łódź Voivodeship, Poland
Amethyst Radiotherapy Center-Oncologie Medicala ( Site 3201)
Florești, Cluj, Romania
Institutul Oncologic-Oncologie Medicala ( Site 3202)
Cluj-Napoca, , Romania
Chelyabinsk Regional Clinical Oncology Dispensary ( Site 2014)
Chelyabinsk, Chelyabinsk Oblast, Russia
GUZ Lipetsk Regional Oncology Dispensary ( Site 2010)
Lipetsk, Lipetsk Oblast, Russia
N.N.Blokhin Russian Cancer Research center ( Site 2013)
Moscow, Moscow, Russia
Russian Scientific Center of Roentgenoradiology ( Site 2011)
Moscow, Moscow, Russia
Medical institute named after Berezin Sergey ( Site 2009)
Saint Petersburg, Sankt-Peterburg, Russia
Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 2000)
Saint Petersburg, Sankt-Peterburg, Russia
Sverdlovsk Regional Oncology Hospital ( Site 2012)
Yekaterinburg, Sverdlovsk Oblast, Russia
Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 2001)
Kazan', Tatarstan, Respublika, Russia
National Cancer Center ( Site 2604)
Goyang-si, Kyonggi-do, South Korea
The Catholic University of Korea St. Vincent s Hospital ( Site 2606)
Gyeonggi-do, Kyonggi-do, South Korea
Chungbuk National University Hospital ( Site 2605)
Cheongju-si, North Chungcheong, South Korea
Seoul National University Hospital ( Site 2600)
Seoul, , South Korea
Samsung Medical Center ( Site 2603)
Seoul, , South Korea
Hospital Universitario Quiron Madrid ( Site 1601)
Pozuelo de Alarcón, Madrid, Spain
Hospital Universitario La Fe ( Site 1603)
Valencia, Valenciana, Comunitat, Spain
Hospital General Universitari Vall d Hebron ( Site 1602)
Barcelona, , Spain
Hospital General Universitario Gregorio Maranon ( Site 1604)
Madrid, , Spain
Hopitaux Universitaires de Geneve HUG ( Site 1706)
Geneva, Canton of Geneva, Switzerland
Universitaetsspital Zuerich ( Site 1700)
Zurich, Canton of Zurich, Switzerland
Tri-Service General Hospital ( Site 3300)
Taipei City, Taipei, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 3304)
Kaohsiung City, , Taiwan
Taipei Medical University Hospital ( Site 3303)
Taipei, , Taiwan
Taipei Veterans General Hospital ( Site 3301)
Taipei, , Taiwan
Baskent Adana Dr Turgut Noyan Uygulama ve Arastirma Merkezi ( Site 2105)
Adana, , Turkey (Türkiye)
Hacettepe University Medical Faculty ( Site 2100)
Ankara, , Turkey (Türkiye)
Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital ( Site 2101)
Ankara, , Turkey (Türkiye)
Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 2116)
Istanbul, , Turkey (Türkiye)
Kartal Training and Research Hospital ( Site 2102)
Istanbul, , Turkey (Türkiye)
I.E.U. Medical Point Hastanesi ( Site 2115)
Izmir, , Turkey (Türkiye)
Erciyes University Medical Faculty ( Site 2109)
Kayseri, , Turkey (Türkiye)
Sakarya Universitesi Tip Fakultesi Hastanesi ( Site 2114)
Sakarya, , Turkey (Türkiye)
Medical center Medikal Plaza of Ecodnipro LLC ( Site 2207)
Dnipro, Dnipropetrovsk Oblast, Ukraine
Regional Centre of Oncology-Thoracic organs ( Site 2202)
Kharkiv, Kharkivs’ka Oblast’, Ukraine
Ukrainian Center of Tomotherapy ( Site 2206)
Kropyvnitskiy, Kirovohrad Oblast, Ukraine
Medical Center of Yuriy Spizhenko LLC.-Clinical Trial ( Site 2205)
Kapitanivka Village, Kyivska Oblast, Ukraine
Medical Center Asklepion LLC ( Site 2208)
Khodosovka, Kyivska Oblast, Ukraine
Medical and Diagnostic Centre LLC Dobryi Prognoz ( Site 2203)
Kyiv, Kyivska Oblast, Ukraine
Kyiv City Clinical Oncology Centre ( Site 2200)
Kyiv, , Ukraine
University Hospitals Bristol NHS Foundation Trust ( Site 1802)
Bristol, Bristol, City of, United Kingdom
Royal Free London NHS Foundation Trust ( Site 1813)
London, Camden, United Kingdom
Weston Park Hospital ( Site 1801)
Sheffield, Derbyshire, United Kingdom
Clatterbridge Cancer Center NHS FT ( Site 1800)
Liverpool, England, United Kingdom
Lancashire Teaching Hospitals NHS Foundation Trust ( Site 1809)
Preston, Lancashire, United Kingdom
Leicester Royal Infirmary ( Site 1811)
Leicester, Leicestershire, United Kingdom
University College London Hospital NHS Foundation Trust ( Site 1806)
London, London, City of, United Kingdom
Guy s and St Thomas Hospital NHS Foundation Trust ( Site 1808)
London, London, City of, United Kingdom
Norfolk and Norwich University Foundation NHS Trust ( Site 1805)
Norwich, Norfolk, United Kingdom
Oxford University Hospitals NHS Foundation Trust ( Site 1812)
Oxford, Oxfordshire, United Kingdom
Darlington Memorial Hospital NHS Trust ( Site 1810)
Darlington, , United Kingdom
Mount Vernon Hospital ( Site 1803)
Northwood, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Swaminath A, Parpia S, Wierzbicki M, Kundapur V, Faria S, Okawara GS, Tsakiridis TK, Ahmed N, Bujold A, Hirmiz K, Owen T, Leong N, Ramchandar K, Filion E, Lau H, Gabos Z, Thompson R, Yaremko B, Mehiri S, Louie AV, Quan K, Levine MN, Wright JR, Whelan TJ. Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Nov;10(11):1571-1575. doi: 10.1001/jamaoncol.2024.3089. Epub 2024 Sep 19.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Plain Language Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-3475-867
Identifier Type: OTHER
Identifier Source: secondary_id
KEYNOTE-867
Identifier Type: OTHER
Identifier Source: secondary_id
194909
Identifier Type: REGISTRY
Identifier Source: secondary_id
2022-500413-11-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
U1111-1275-8515
Identifier Type: REGISTRY
Identifier Source: secondary_id
2018-004320-11
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
3475-867
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.